Bilateral Laparoscopic Salpingectomy
Conditions
Keywords
salpingectomy, optical biopsy, Cellvizio®
Brief summary
High-grade serous ovarian cancer is the most threatening type of gynaecological cancer with an important mortality due to late diagnosis. However the prognosis is excellent in the early stages of the disease. Recently it has been described a new serous carcinogenic sequence from the fallopian tube with tubal precancerous lesions. Therefore the identification of these early preinvasive lesions would be of great interest in the population with hereditary predisposition for ovarian cancer (concept of oncofertility) and in the general population (to determine whether bilateral salpingectomy has to be performed during a hysterectomy for benign disease). The optical biopsy has been developed and validated in the detection of early precancerous lesions (such as Barrett's oesophagus or in situ cancer of the bladder). The first objective of this study is to prospectively assess the efficacy of optical biopsy (Cellvizio®) in the study of fallopian tubes during laparoscopy with correlation between the histopathological and immunohistochemical analysis and the endomicroscopy image interpretation. The second objective is to describe the optical biopsy pictures in order to state a classification.
Detailed description
Inclusion Criteria: * Woman aged 18 years or more * All patients with laparoscopic salpingectomy for benign conditions (tubal ligation, during a hysterectomy), for prophylactic conditions (BRCA mutation) or in case of pelvic cancers * Informed and signed consent Exclusion Criteria: * Interview revealing disorder entailing unacceptable risk of postoperative complications: coagulation disorder, immune system disorder, evolutive disease, etc. * Pregnancy, ongoing or planned during the study period * Allergy to fluorescein * Previous allergy or anaphylactic shock during an angiography * Allergic or hypersensibility reactions * Severe asthma, chronic cardiac or pulmonary diseases * Restricted renal function * Patient under a beta-blockers treatment * Inability to understand information provided * Not covered by a national health insurance scheme, prisoner or under administrative supervision
Interventions
PROCEDUREbilateral laparoscopic salpingectomy
Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
DEVICEendomicroscopy Cellvizio® system
Sponsors
Hospices Civils de Lyon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Woman aged 18 years or more * All patients with laparoscopic salpingectomy for benign conditions (tubal ligation, during a hysterectomy), for prophylactic conditions (BRCA mutation) or in case of pelvic cancers * Informed and signed consent
Exclusion criteria
* Interview revealing disorder entailing unacceptable risk of postoperative complications: coagulation disorder, immune system disorder, evolutive disease, etc. * Pregnancy, ongoing or planned during the study period * Allergy to fluorescein * Previous allergy or anaphylactic shock during an angiography * Allergic or hypersensibility reactions * Severe asthma, chronic cardiac or pulmonary diseases * Restricted renal function * Patient under a beta-blockers treatment * Inability to understand information provided * Not covered by a national health insurance scheme, prisoner or under administrative supervision
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between the histopathological and immunohistochemical analysis and the endomicroscopy image interpretation | DAY 1 |
Secondary
| Measure | Time frame |
|---|---|
| : Description of the optical biopsy pictures in order to state a classification | DAY 1 |
Countries
France
Outcome results
None listed